Activated protein C resistance: Clinical implications

Clinical and Applied Thrombosis/Hemostasis

Volumn 3, Issue 1, 1997, Pages 25-32

  Zöller, Bengt ^a   Hillarp, Andreas ^a   Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

APC resistance; Factor V; Mutation; Protein C; Protein S; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5A;

ACTIVATED PROTEIN C RESISTANCE; CLINICAL FEATURE; HYPERCOAGULABILITY; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; SCREENING; THROMBOGENESIS;

EID: 0031429316     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969700300103     Document Type: Review

References (100)

1. Hirsh J, Hull RD, Raskob GE, Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol 1986;8: 104-13B.
2. Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - critical evaluation of laboratory investigation. Thromb Haemost 1992;68:7-13.
3. Heijboer H, Brandjes D, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990;323:1512-6.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
5. Griffin JH, Evatt BL, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993;82:1989-93.
6. Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-6.
7. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-21.
8. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 1993;70:1067-71.
9. Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994;5:51-7.
10. Liu HW, Kwong YL, Bourke C, et al. High incidence of thrombophilia detected in Chinese patients with venous thrombosis. Thromb Haemost 1994;71:416-9.
11. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
12. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt BL. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1362-3.
13. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994;343:1535-6.
14. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-8.
15. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosisprone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
16. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995;74:1-6.
17. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988;53:505-18.
18. Broze GJ. The tissue factor pathway of coagulation: factor VII, tissue factor, and tissue factor pathway inhibitor. In: Bloom AL, Forbes CD, Thomas DP, Tuddenhamn EGD, eds. Haemostasis and thrombosis. 3rd ed. Edinburgh: Churchill Livingstone, 1995:349-77.
19. Kane WH, Davie EW. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988;71:539-55.
20. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann Rev Biochem 1988;57:915-56.
21. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995;5:141-8.
22. Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77:1-43.
23. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995;9:946-55.
24. Walker FJ. Regulation of activated protein C by a new protein. J Biol Chem 1980;255:5521-4.
25. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 1994;269:18735-8.
26. Váradi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII. Thromb Haemost 1995;73:730-1.
27. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994;91:1396-400.
28. Sun X, Evatt BL, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994;83:3120-5.
29. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994;269:31869-80.
30. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995;270:4053-7.
31. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995;85:3405-11.
32. Rosing J, Hoekema L, Nicolaes GAF, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995;270:27852-8.
33. Nicolaes GAF, Tans G, Thomassen MCLGD, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995;270:21158-66.
34. Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance based on studies using purified FV:Q506. Biochem J 1996;313:467-72.
35. Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990;16:299-309.
36. Zöller B, Holm J, Svensson PJ, Dahlbäck B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with inherited APC-resistance and/or protein S deficiency. Thromb Haemost 1996;75:270-4.
37. Simioni P, Scarano L, Gavasso S, et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC-resistance due to factor V Leiden mutation. Br J Haematol 1996;92:435-41.
38. Leroy Matheron C, Levent M, Pignon J, Mendonca C, Gouault Heilmann M. The 1691 G → A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost 1996;75:4-10.
39. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C Resistance). Blood 1995;85: 1504-8.
40. Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and MnlI in genotype (Gln506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995;74:996.
41. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
42. de Maat MPM, Kluft C, Jespersen J, Gram J. World distribution of factor V Leiden mutation. Lancet 1996;347:58.
43. Braun A, Müller B, Rosche AA. Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C. Hum Genet 1996;97:263-4.
44. Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation among myocardial infarction patients and healthy controls higher in Sweden than in other countries. J Intern Med 1996;239:221-6.
45. Zöller B, Dahlbäck B. Resistance to activated protein C caused by a factor V gene mutation. Curr Opin Hematol 1995;2:358-64.
46. Woo KS, Tse LKK, Tse CY, Metreweli C, Vallance-Owen J. The prevalence and pattern of pulmonary thromboembolism in the Chinese in Hong Kong. Int J Cardiol 1988;20: 373-80.
47. Thomas WA, Davies JNP, O'Neal RM, Dimakulangan AA. Incidence of myocardial infarction correlated with venous and pulmonary thrombosis and embolism. A geographic study based on autopsies in Uganda, East Africa and St. Louis, USA. Am J Cardiol 1960;5:41-7.
48. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
49. Liu XY, Nelson D, Grant C, Morthland V, Goodnight SH, Press RD. Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. Diagn Mol Pathol 1995;4: 191-7.
50. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995;15:783-5.
51. Arruda VR, Annichino-Bizzacchi JM, Costa FF, Reitsma PH. Factor V Leiden (FVQ 506) is common in a brazilian population. Am J Hematol 1995;49:242-3.
52. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232: 155-60.
53. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg → Gln mutation in the gene for factor V. N Engl J Med 1994; 331:1559-62.
54. Majerus, PW. Bad blood mutation. Nature 1994;369:14-5.
55. Hopmeier P, Krugluger W. Factor V Leiden and thrombophilia. N Engl J Med 1995;332:1381-2.
56. Simioni P, Scudeller A, Girolami A. Factor V Leiden and thrombophilia. N Engl J Med 1995;332:1382.
57. Koeleman BPC, Reitsma PH, Allaart RC, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994;84: 1031-5.
58. Koeleman BPC, van Rumpf D, Hamulyák K, Reitsma PH, Bertina RM. Factor V Leiden. An additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995;74:580-3.
59. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518-23.
60. Beufé S, Borg JY, Vasse M, et al. Co-segregation of thrombosis with the factor V Q506 mutation in an extended family with resistance to activated protein C. Br J Haematol 1995; 89:659-62.
61. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-3.
62. Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996;92:473-8.
63. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
64. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
65. Bridey F, Wolff.M. JP, Morin V, Lefebvre M, de Prost D. Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost 1995;74:1382.
66. Levoir D, Emmerich J, Alhenc Gelas M, et al. Portal vein thrombosis and factor V Arg 506 to Gln mutation. Thromb Haemost 1995;73:550-1.
67. Press RD, Liu XY, Beamer N, Coull BM. Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke 1996;27:44-8.
68. Kontula K, Ylikorkala A, Miettinen H, et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995;73:558-60.
69. van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nature Med 1995;1:185.
70. Emmerich J, Poirier O, Evans A, et al. Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995;345:321.
71. Samani N, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction. Lancet 1994;344:1709-10.
72. Forsyth PD, Dolan G. Activated protein C resistance in cases of cerebral infarction. Lancet 1995;345:795.
73. Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 1994;72:647.
74. Eritsland J, Gjonnes G, Sandset PM, Seljeflot I, Arnesen H. Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res 1995;79: 223-6.
75. Biasiutti FD, Merlo C, Furlan M, Sulzer I, Binder BR, Lämmle B. No association of APC-resistance with myocardial infarction. Blood Coagul Fibrinolysis 1995;6:456-9.
76. März W, Seydewitz H, Winkelmann B, Chen M, Nauck M. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995;345:526-7.
77. Ouriel K, Green RM, Deweese JA, Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease. J Vasc Surg 1996;23:46-52.
78. Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344:952-3.
79. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995;74:449-53.
80. Engel H, Zwang L, van Vliet HHDM, Michiels JJ, Stibbe J, Lindemans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost 1996;75:267-9.
81. Jorquera JI, Montoro JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994;344:1162-3.
82. Trossaërt M, Conard J, Horellou MH, et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994;344:1709.
83. Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995;73:732-3.
84. Cadroy Y, Sié P, Alhenc Gelas M, Aiach M. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995;73:734-5.
85. Dahlbäck B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995;73:739-42.
86. Jaksch M, v Reuss-Krausse K, Schneppenheim R, Hofmann S, Kaufhold P, Gerbitz KD. Activated protein C (APC)-resistance: Screening of the factor V G1691A mutation using SSCP [Abstract]. Ann Hematol 1995;70(suppl): A64.
87. Gandrille S, Alhenc Gelas M, Aiach M. A rapid screening method for the factor V Arg506 → Gln mutation. Blood Coagul Fibrinolysis 1995;6:245-8.
88. van de Locht LTF, Kuypers AWHM, Verbruggen BW, Linssen PCM, Nováková IRO, Mensink EJBM. Semiautomated detection of the factor V mutation by allele specific amplification and capillary electrophoresis. Thromb Haemost 1995;74:1276.
89. Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thromb Haemost 1995;74:874-8.
90. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996;92:489-90.
91. De Lucia D, De Blasio G, Belli A, et al. High prevalence of activated protein C resistance in patients with systemic sclerosis. Int J Clin Lab Res 1996;25:226-7.
92. Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995;74:94-100.
93. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2.
94. Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter Ch. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996;75: 229-32.
95. Lindblad B, Svensson PJ, Dahlbäck B. Arterial and venous thromboembolism with fatal outcome in a young man with inherited resistance to activated protein C. Lancet 1994; 343:917.
96. Simioni P, de Rode H, Prandoni P, Saladini M, Bertina RM, Girolami A. Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke 1995;26:885-90.
97. Ganesan V, Kelsey H, Cookson J, Osborn A, Kirkham FJ. Activated protein C resistance in childhood stroke. Lancet 1996;347:260.
98. Zöller B, He X, Dahlbäck B. Homozygous APC-resistance combined with protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995;73: 743-5.
99. van Boven HH, Reitsma PH, Rosendaal FR, et al. Interaction of factor V Leiden with inherited antithrombin deficiency [Abstract]. Thromb Haemost 1995;73:1256.
100. Gandrille S, Greengard JS, Alhenc Gelas M, et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995;86:219-24.